Joule Unlimited Forges a Faster Path to Biofuels

Joule Unlimited Forges a Faster Path to Biofuels

October 16, 2011

Joule Unlimited Technologies Inc. won the Silver in this year's Wall Street Journal Technology Innovation Awards for developing a more efficient technique for producing biofuel.

The Cambridge, Mass.-based company has created genetically engineered micro-organisms that secrete ethanol, diesel fuel and other hydrocarbons from water, sunlight and carbon dioxide. The use of these patented organisms eliminates some of the costly processing steps needed to turn plants into motor fuel.

Click on WSJ logo to view full article

Quanterix Corporation

Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery

Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery

October 13, 2011

CAMBRIDGE, Mass. -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrating that the assay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).  The pilot study was published online by the British Journal of Urology International. 

Black Duck Software, Inc.

Black Duck Software Secures $12 Million in New Funding Round Led By Split Rock Partners

Black Duck Software Secures $12 Million in New Funding Round Led By Split Rock Partners

October 13, 2011

Waltham, Mass. -- Black Duck Software, the leader in open source software knowledge, adoption and governance, today announced it has closed a $12M round of financing led by new investor Split Rock Partners, with participation from its existing investors as well. The company, which has been cash-flow positive since 2009, will use the funds to accelerate growth, advance key development projects, continue acquisitions and expand its global presence

Avedro, Inc.

Avedro Appoints A. John Kanellopoulos, MD to Its Medical Advisory Board

Avedro Appoints A. John Kanellopoulos, MD to Its Medical Advisory Board

October 13, 2011

WALTHAM, Mass.-- Avedro, Inc., a privately held medical device and pharmaceutical company, today announced A. John Kanellopoulos, MD has been named to its Medical Advisory Board. Dr. Kanellopoulos is a Clinical Professor of Ophthalmology at the NYU School of Medicine and Director of the Laser Vision Institute, Athens, Greece.

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients

Alvine Pharmaceuticals Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients

October 11, 2011

SAN CARLOS, CA -- Alvine Pharmaceuticals, Inc. today announced positive results from its Phase 2a clinical trial of ALV003, which demonstrated the ability of ALV003 to attenuate gluten-induced intestinal mucosal injury in serologically negative celiac disease patients maintained on a gluten-free diet for one or more years. The study findings will be presented in a late breaking oral session at the 19th United European Gastroenterology Week (UEGW) in Stockholm on October 24.

Agios Pharmaceuticals, Inc.

Celgene and Agios Extend Cancer Metabolism Collaboration

Celgene and Agios Extend Cancer Metabolism Collaboration

October 5, 2011

CAMBRIDGE, Mass., Oct 05, 2011 -- Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that Celgene Corporation (NASDAQ: CELG) and Agios have agreed, ahead of schedule, to extend the initial period of exclusivity of the companies' April 2010 collaboration agreement from three to four years. During this period, Celgene has an exclusive option to drug candidates generated by Agios' cancer metabolism research platform.

Avedro, Inc.

Avedro Appoints C. Evan Ballantyne as Chief Financial Officer

Avedro Appoints C. Evan Ballantyne as Chief Financial Officer

September 28, 2011

WALTHAM, Mass., Sep 28, 2011 -- Avedro, Inc., a privately held medical device and pharmaceutical company, today announced C. Evan Ballantyne as Chief Financial Officer. In this position, Mr. Ballantyne will be responsible for the Company's financial affairs and report to David Muller, PhD, President and Chief Executive Officer. Prior to this role, Mr. Ballantyne served as Executive Vice President, Chief Financial Officer of Clinical Data, Inc., a biopharmaceutical company which was acquired in April 2011 by Forest Laboratories, Inc. for $1.3 billion.

Theracrine Appoints Steven Kelly as President and CEO

Theracrine Appoints Steven Kelly as President and CEO

September 27, 2011

CAMBRIDGE, Mass., Sep 27, 2011 -- Theracrine, Inc., the first biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer spread, today announced the appointment of Steven Kelly as President and Chief Executive Officer.

Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer;

Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer;

September 22, 2011

Cambridge, Mass. – September 22, 2011 – Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing innovative protein-based therapeutics, today announced the appointment of industry veteran Abbie Celniker, Ph.D., as chief executive officer.  Most recently, Dr. Celniker served as president and chief executive officer at Taligen Therapeutics, where she was instrumental in building the company to its acquisition by Alexion in January 2011.

Mascoma Corporation

Mascoma Corporation Files Registration Statement for Proposed Initial Public Offering

Mascoma Corporation Files Registration Statement for Proposed Initial Public Offering

September 19, 2011

Lebanon, New Hampshire - September 19, 2011 - Mascoma Corporation announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. Morgan Stanley & Co. LLC, UBS Securities LLC and Credit Suisse Securities (USA) LLC will act as joint book-running managers for the offering with Robert W. Baird & Co. and Canaccord Genuity Inc. acting as co-managers.